-The Telegraph New Delhi: Many doctors across India have been offered prepaid cash cards as gifts by drug industry representatives over the past three years to try and influence prescriptions for patients, Pharmaceuticals sales executives have said. While drug companies have long used largesse as "brand reminders" for doctors, a prepaid cash card leaked by an industry whistleblower appears to be the first evidence to suggest doctors are also being offered cash...
More »SEARCH RESULT
Total Matching Records found : 184
Drug price control covers too little, riddled with loopholes -GS Mudur
-The Telegraph New Delhi: The price caps imposed by the Indian government on 348 drugs earlier this year have created only an illusion of control, keeping many medicines for conditions ranging from asthma to diabetes and heart disease beyond price regulations, experts said today. The price control order issued by the department of Pharmaceuticals in May has led to a 22 per cent reduction in the average cost of some 250 medicines,...
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of Pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan
-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...
More »Indian drug makers face heat of US regulator's crackdown-Sushmi Dey
-The Business Standard Data also show that several other leading domestic pharma companies have recalled their products from the US Frequent drug recalls, warning letters and import alerts from the US in the recent past have turned into a major concern for the Indian pharmaceutical industry and investors. While Ranbaxy Laboratories recently pleaded guilty before the US authorities for its wrongdoings in the past, the crackdown on the drug companies seems to...
More »
